No Data
Xiamen Amoytop Biotech (688278.SH): donated 9 million yuan to the China Hepatitis Prevention and Treatment Fund.
On March 7, 2023, Xiamen Amoytop Biotech (688278.SH) announced that the company's ninth Board of Directors held its sixth meeting on March 7, 2025, unanimously approving the proposal for external donations. The company decided to donate 9 million yuan to the China Hepatitis Prevention and Control Foundation (hereinafter referred to as the "Foundation"), for the public welfare project aimed at controlling high-risk populations related to hepatitis B virus (HBV) and liver cancer.
Is Xiamen Amoytop Biotech Co., Ltd.'s (SHSE:688278) Latest Stock Performance A Reflection Of Its Financial Health?
Tebao Biotech: Tepo Biotech: 2024 Annual Results Report Announcement
Tebao Biotech: 2024 Annual Results Report Announcement
Xiamen Amoytop Biotech (688278.SH): The net income for the fiscal year 2024 is 0.828 billion yuan, an increase of 49.00% year-on-year.
Gelonghui, February 25th丨Xiamen Amoytop Biotech (688278.SH) announced its 2024 annual performance report. During the reporting period, the company's operating performance maintained steady growth, achieving a total operating income of 2.817 billion yuan, a year-on-year increase of 34.13%; achieving a net income attributable to the parent company's owners of 0.828 billion yuan, a year-on-year increase of 49.00%; achieving a net income attributable to the parent company's owners after deducting non-recurring gains and losses of 0.827 billion yuan, a year-on-year increase of 42.73%. During the reporting period, the company’s main business remained robust, particularly as the clinical cure research for hepatitis B continued to deepen, the company's product Pegasys, as a chronic
Xiamen Amoytop Biotech to Acquire Skyline Therapeutics Assets for $15 Million
Here's Why We Think Xiamen Amoytop Biotech (SHSE:688278) Might Deserve Your Attention Today